First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811

Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combinatio...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Future oncology (London, England) England), 2021-02, Vol.17 (5), p.491-501
Hauptverfasser:	Chung, Hyun Cheol, Bang, Yung-Jue, S Fuchs, Charles, Qin, Shu-Kui, Satoh, Taroh, Shitara, Kohei, Tabernero, Josep, Van Cutsem, Eric, Alsina, Maria, Cao, Zhu Alexander, Lu, Jia, Bhagia, Pooja, Shih, Chie-Schin, Janjigian, Yelena Y
Format:	Artikel
Sprache:	eng
Schlagworte:	chemotherapy Clinical Trial Protocol first-line therapy gastric cancer gastroesophageal junction cancer human epidermal growth factor receptor 2 pembrolizumab trastuzumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!